We recently published a list of Top 11 AI News Updates on Wall Street’s Radar. In this article, we are going to take a look ...

The latest trading session saw Lam Research (LRCX) ending at $77.67, denoting a -0.41% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 0.16% for ...

Below is Validea's guru fundamental report for LAM RESEARCH CORP (LRCX). Of the 22 guru strategies we follow, LRCX rates highest using our Patient Investor model based on the published strategy of ...

Lam Research (LRCX) ended the recent trading session at ... Meanwhile, the Dow gained 0.85%, and the Nasdaq, a tech-heavy index, added 0.31%. Shares of the semiconductor equipment maker witnessed ...

Lam Research (LRCX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

Columbia Threadneedle Investments, an investment management company released its “Columbia Seligman Global Technology Fund” ...

Oppenheimer began coverage on shares of Lam Research (NASDAQ:LRCX – Free Report) in a research report released on Thursday morning. The brokerage issued an outperform rating and a $95.00 target price ...

We recently published a list of Jim Cramer’s Latest Lightning Round: 7 Stocks in Focus. In this article, we are going to take ...

Lam Research (NASDAQ:LRCX) received an Outperform rating as financial services firm Oppenheimer initiated coverage of the ...

So, it is worth exploring what lies ahead for the stock. Investing.com -- Oppenheimer initiated coverage on Lam Research Corp (NASDAQ:LRCX) with an Outperform rating and a price target of $95 ...

Below is Validea's guru fundamental report for LAM RESEARCH CORP (LRCX). Of the 22 guru strategies we follow, LRCX rates highest using our Patient Investor model based on the published strategy of ...

Below is Validea's guru fundamental report for LAM RESEARCH CORP (LRCX). Of the 22 guru strategies we follow, LRCX rates highest using our Patient Investor model based on the published strategy of ...